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Abstract: Conventional drugs used for antibacterial therapy display several limitations. This is not due
to antibiotics being ineffective, but rather due to their low bioavailability, limited penetration to sites of
infection and the rise of drug-resistant bacteria. Although new delivery systems (e.g., nanoparticles)
that are loaded with antibacterial drugs have been designed to overcome these limitations, therapeutic
efficacy does not seem to have improved. Against this backdrop, stimuli-responsive antibiotic-loaded
nanoparticles and materials with antimicrobial properties (nanoantibiotics) present the ability to
enhance therapeutic efficacy, while also reducing drug resistance and side effects. These stimuli can
either be exogenous (e.g., light, ultrasound) or endogenous (e.g., pH, variation in redox gradient,
enzymes). This promising therapeutic approach relies on advances in materials science and increased
knowledge of microorganism growth and biofilm formation. This review provides an overview in
the field of antibacterial drug-delivery systems and nanoantibiotics that benefit from a response to
specific triggers, and also presents a number of future prospects.
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stimuli-responsive nanoparticles; stimuli-responsive antibiotic-loaded nanoparticles; nanoantibiotics;
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1. Introduction
Antimicrobial resistance (AMR) is now considered an emergent global disease and a major public
health problem. Epidemiological data from the World Health Organization (WHO) report that there
has been an increase in AMR rates in recent years and that this worrying trend is not limited to specific
pathogens or to a specific geographical area [1]. AMR is now the second-leading cause of deaths
worldwide and the third in the USA, meaning that new strategies to either enhance the effectiveness
of existing antibiotics or for the development of new antibiotics are very much needed if this public
health emergency is to be addressed by counteracting antibiotic resistance.
Nanoparticle drug-delivery systems are an attractive tool for the treatment of infections. This is
thanks to their significant and unique features, such as the improved solubility of hydrophobic
antibiotics, prolonged systemic-circulation time and antibiotic half-life, and sustained antibiotic
release, all of which may be able to reduce systemic side effects and allow lower drug doses to
be administered [2]. A number of improved drug carriers have been developed for the treatment
of intracellular pathogens, including antibiotics that are loaded into liposomes and other lipid
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nanoformulations, silica nanoparticles, microspheres, polymeric carriers, fullerenes, dendrimers and
nanoplexes [3,4].
The first generation of drug carriers that was approved for such applications (e.g., Albecet;
Sigma-Tau Pharmaceuticals-Ambisome; Astellas Pharma-Amphotec; Ben Venue Laboratories-Arikace;
Transave) was primarily based on liposomes, which are spherical vesicles with a lipid bilayer membrane
structure that can encapsulate both hydrophilic and hydrophobic agents, thus protecting the cargo (for
example small-molecule drugs, nucleotides, proteins, imaging agents or radionucleotides) during its
circulation throughout the body [5,6]. They can also be functionalised, for example, with ligands to
cell-surface receptors to promote targeting to specific cells and tissues. In addition, they can be coated
with polymers to prolong circulation half-life [7,8]. However, although the advantages of liposomes as
a drug-delivery system are widely recognised, they also possess some disadvantages for antimicrobial
treatment purposes. These include their short shelf-life and stability, encapsulation efficacy and their
rapid clearance from the blood stream by phagocytic cells of the mononuclear phagocyte system
(MPS), which is also referred to as the reticuloendothelial system (RES) [9]. In addition, the design
of an optimal drug carrier for the release of antibiotics must always take into consideration the most
important points in antibiotic treatment: (i) improving antimicrobial-treatment efficacy; (ii) increasing
local drug concentration at the site of the infection; (iii) minimising antibiotic accumulation in healthy
host tissue; (iv) reducing the risks of toxicity and the exposure of commensal microflora to sub-lethal
doses of antibiotics, which can promote the development of antimicrobial resistance [10]. The design of
stimuli-responsive systems that either recognise the bacterial microenvironment and react in a dynamic
way, or that are susceptible to specific physical stimulation, is therefore one of the possible ways to
improve antibiotic drug-delivery systems and enhance their targeting properties, efficiency and the
efficacy of antibiotic therapies while, at the same time, minimising side effects and developing new
strategies against AMR.
The idea of stimuli-responsive systems was first introduced in the late 1970s with the use of
thermosensitive liposomes for the local release of drugs through hyperthermia [11]. Since then, a vast
body of research on stimuli-responsive materials, and especially on their design and applications,
has been accumulated [12]. Nanoscale stimuli-responsive devices can be sensitive to specific
intracellular stimuli, such as pH, the varying concentrations of certain enzymes or chemical compounds
(e.g., glutathione). They can also be sensitive, on the tissue level, to specific microenvironmental
changes that are associated with pathological conditions such as inflammatory disease, ischemia and,
of course, infections. Furthermore, sustained drug release and improvements in inherent therapeutic
nanomaterials can be achieved by extracorporeal physical stimuli, such as magnetic-, thermal-, light-
and ultrasound (US)-sensitive nanoparticle systems. In this regard, stimuli-responsive drug-delivery
systems can provide antibiotic drug-delivery systems with a great many advantages (Figure 1),
including enhancing the targeting properties, efficiency and efficacy of antibiotic therapies while, at the
same time, minimising their side effects. Indeed, the emergence and dissemination of drug-resistant
pathogens entails the necessity of decreasing doses while increasing treatment efficacy. The use of
external or internal stimuli to influence the antibiotic activity of responsive drug-delivery systems
can lead to smart therapeutic responses such as: (i) controlled release of payload in the targeted
biological compartment and (ii) rapidly addressing the pathological event. Furthermore, an important
feature of this type of approach is the reversibility since the antibiotic nanosystem may return to its
initial state upon application of the specific stimulus. In this review, we provide an overview of the
current progress in the field of stimuli-responsive drug delivery systems (DDSs) and stimuli-responsive
therapeutic nanoparticles for the management of microbial infection and AMR.
Molecules 2019, 24, 1991 3 of 15
Molecules 2019, 24, x FOR PEER REVIEW 3 of 15 
 
 
Figure 1. Schematic illustration of stimuli-responsive antibiotic drug-delivery systems. Lipid-based, 
polymeric and inorganic nanoparticles are the most studied stimuli-responsive drug delivery systems 
for antibiotic drugs. 
2. Exogenous Stimuli-Responsive Antibiotic Drug-Delivery Systems 
Effort in the development of stimuli-responsive drug-delivery systems has traditionally been 
focused on the synthesis and modification of biomaterials, such as polymers and lipids, in order to 
provide them with a wide range of chemical functionalities that readily undergo hydrolysis, 
enzymatic degradation, or conformational changes in response to either chemical (e.g., pH, ionic 
strength, reactive oxygen species), physical (e.g., temperature, light, ultrasound ), or biological (e.g., 
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NPs with traditional drug-delivery systems, such as liposomes, polymersomes and hydrogels, is a 
promising and emerging approach to the stimuli-responsive release of antibiotics [13]. This 
development is underpinned by the rapid advancements that have been made in the synthesis of 
monodispersed and biocompatible inorganic NPs with a wide range of surface functionalisation and 
physicochemical properties. The selective release of therapeutic cargo from the drug-delivery 
systems in response to a variety of remotely applied and local stimuli, such as light irradiation, 
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The unique optical and magnetic properties of inorganic NPs have been harnessed for the 
photothermal- and magnetothermal-mediated release of therapeutics from drug delivery systems. 
This is thanks to the ease of achieving selective drug-carrier disruption via the external application 
of a laser or alternating magnetic field. The generation of heat from activated inorganic NPs that are 
incorporated into drug-delivery systems also enhances the antibacterial efficiency of the delivered 
antibiotics through synergistic thermal-ablative effects [14]. 
2.1.1. Photothermal Release 
Photothermal heating occurs due to the absorption of light by an ensemble of electrons on the 
surface of certain conductive materials and the subsequent dissipation of that energy as heat. 
Plasmonically active metal NPs, such as Au NPs, Ag NPs, and Cu NPs, are particularly effective 
photothermal agents because of their large absorbance cross sections, tunable optical properties, and 
highly efficient conversion of light into heat [15]. In such metallic NPs, most of the energy gained by 
the electrons during photo-excitation at this resonance is dissipated as heat, through electron-photon 
collisions, leading to the heating of the NPs and the surrounding environment. Photothermal heating 
Figure 1. Schematic illustration of stimuli-responsive antibiotic drug-delivery systems. Lipid-based,
polymeric and inorganic nanoparticles are the most studied stimuli-responsive drug delivery systems
for antibiotic drugs.
2. Exogenous Stimuli-Responsive Antibiotic Drug-Delivery Systems
Effort in the development of stimuli-responsive drug-delivery systems has traditionally been
focused on the synthesis and modification of biomaterials, such as polymers and lipids, in order to
provide them with a wide range of chemical functionalities that readily undergo hydrolysis, enzymatic
degradation, or conformational changes in response to either chemical (e.g., pH, ionic strength,
reactive oxygen species), physical (e.g., temperature, light, ultrasound ), or biological (e.g., proteolytic
enzymes) stimuli and thus induce therapeutic-cargo release. In this regard, the co-formulation of
metallic inorganic nanoparticles (NPs) such as Au NPs, Ag NPs, Fe2O3 NPs and Fe3O4 NPs with
traditional drug-delivery systems, such as liposomes, polymersomes and hydrogels, is a promising
and emerging approach to the stimuli-responsive release of antibiotics [13]. This development is
underpinned by the rapid advancements that have been made in the synthesis of monodispersed
and biocompatible inorganic NPs with a wide range of surface functionalisation and physicochemical
properties. The selective release of therapeutic cargo from the drug-delivery systems in response to a
variety of remotely applied and local stimuli, such as light irradiation, magnetic fields, and pH, can be
achieved by harnessing the unique optical, magnetic, and/or physicochemical properties of metallic
inorganic NPs.
2.1. Thermal Release
The unique optical and magnetic properties of inorganic NPs have been harnessed for the
photothermal- and magnetothermal-mediated release of therapeutics from drug delivery systems.
This is thanks to the ease of achieving selective drug-carrier disruption via the external application
of a laser or alternating magnetic field. The generation of heat from activated inorganic NPs that are
incorporated into drug-delivery systems also enhances the antibacterial efficiency of the delivered
antibiotics through synergistic thermal-ablative effects [14].
2.1.1. Photothermal Release
Photothermal heating occurs due to the absorption of light by an ensemble of electrons on
the surface of certain conductive materials and the subsequent dissipation of that energy as heat.
Plasmonically active metal NPs, such as Au NPs, Ag NPs, an Cu NPs, are particularly effective
photothermal agents because of their large absorbance cross sections, tunable optical properties,
and highly efficient conversion of light into heat [15]. In such metallic NPs, most of the energy gaine
by the electrons during photo-excitation at this resonance is dissipated as heat, through electron-photon
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collisions, leading to the heating of the NPs and the surrounding environment. Photothermal heating
can either be used to deliver thermal energy to a localised area as reported by Khan and colleagues in
their research work [16], or, alternatively, throughout the drug carrier, thereby causing the destruction
of the encapsulating material and triggering the release of the loaded therapeutics. Some early
demonstrations of the use of photothermal effects to release antibacterial agents from drug carriers
have been reported in a number of research studies [17–20].
In Radt et al. [17], lysozyme crystal and Au NPs were embedded into a polyelectrolyte shell
built from the layer-by-layer deposition of negatively charged poly(sodium 4-styrenesulfonate) and
positively charged poly(allylamine hydrochloride). The capsules were first irradiated with a 10 ns
pulsed laser (λ = 1064 nm) at 50 mJ cm−2 for 5 min at a frequency of 10 Hz before being added to
a suspension of Micrococcus lysodeikticus. The release of lysozymes from photothermally degraded
capsules led to rapid bacterial digestion being observed. In the work by Amoli-Diva and co-workers [18],
Ag NPs were embedded within a poly(butyl methacrylate-co-acrylamide-co-methacrylic acid) hydrogel
to provide the controlled release of the model antibiotic ofloxacin following irradiation with a 405 nm
laser for 15 s at the 10, 30 and 50 min after the start of the experiment. After 70 min, a significantly
higher amount of ofloxacin (>80% of total mass) was released from these samples than from the
non-irradiated samples.
In a further study, Liu et al. [19], developed an efficient antimicrobial hybrid for combined
chemo-photothermal therapy that is based on polydopamine (PDA)-coated gold nanorods (GNRs).
The PDA coating achieved high silver-ion loading efficiency and glycol chitosan (GCS) functionalisation
(Ag+-GCS-PDA@GNRs). The authors tested their bactericide hybrid on in vitro co-cultured
drug-resistant Gram-positive methicillin-resistant Staphylococcus aureus (MRSA) or Gram-negative
Escherichia coli. Furthermore, photothermal therapy was introduced to construct a chemo-photothermal
combinational bactericide system and further improve the antibacterial effect. The test samples were
therefore further irradiated with an 808 nm-laser at 0.5 W cm−2 for 7 min. The bacterial inactivation
percentages for the Ag+-GCS-PDA@GNRs + near-infrared (NIR) treatment group were 99.6 and
96.8% for MRSA and Escherichia coli, respectively. In addition, in vivo biocompatibility and in vivo
antibacterial activity was also investigated using a murine subcutaneous abscess model. In the animal
group where Ag+-GCS-PDA@GNRs were intravenously injected and further exposed to 808 nm
NIR irradiation for 6 min at 0.8 W cm−2, the mice showed no evident inflammation and abscess.
In conclusion, the authors suggest that this antimicrobial depot will be able to circulate freely in
the bloodstream and accumulate in acidic infectious sites where they become positively charged,
and selectively target negatively-charged bacteria-cell surfaces. With external light-activation, they will
generate heat in the close vicinity of the target bacteria. The acidity/thermally-triggered Ag+ ion release
may reduce the heat resistance of the bacteria and photothermal therapy may promote the antibacterial
efficiency of the Ag+ ions.
In the work by Borzenkov and colleagues [20], poly(vinyl alcohol) (PVA) films containing
five-branched gold nanostars were developed and displayed a pronounced photothermal effect upon
irradiation at three NIR laser wavelengths (λ = 730, 800 and 1064 nm). It was shown that the
local NIR-induced increase of temperature was sufficient to eradicate Escherichia coli grown on the
film surface.
2.1.2. Ultrasound Release
Thermal release has also been exploited for the mechanical disruption of drug carriers via US
exposure [21,22]. In the study by Wu et al. [23], the pulsed-laser irradiation of liposomes that either
encapsulated hollow gold nanoshells (HGNs) or that were mixed with free HGNs triggered the release
of encapsulated 6-carboxyfluorescein (CF), a fluorescent dye, above a threshold of ≈1.5 W cm−2 without
the induction of permanent liposomal damage or drastic temperature increases to the bulk solution.
This suggests that triggered CF release occurred due to transient cavitation effects. The authors
suggested that the water molecules surrounding the HGN vaporise at sufficiently high temperatures to
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form a gaseous cavity that violently expands and collapses. This is analogous to the transient cavitation
effects of microbubbles in response to applied US. The collapse of the vapour bubble subsequently
emits a shock wave that propagates through the surrounding medium to transiently disrupt liposome
membranes and thus release the encapsulated cargo.
In this regard, US appears to be paying an ever-increasing role in the delivery of therapeutic
agents, including genetic material, proteins and chemotherapeutic agents, such as antibiotics, via micro-
or nano-bubble cavitation, without the involvement of bulk heating [24]. Cavitation is the formation
and/or activity of gas-filled bubbles in a medium that is exposed to US. As the pressure wave passes
through the media, gas bubbles of any size will expand at low pressure and contract at high pressure.
If the resulting oscillation in bubble size is fairly stable (repeatable over many cycles), the cavitation
is called “stable” or “non-inertial” cavitation. This type of oscillation creates a circulating fluid flow
(called microstreaming) around the bubble, with velocities and shear rates that are proportional to the
amplitude of the oscillation. At high amplitudes, the associated shear forces are capable of shearing
open red-blood cells and synthetic vesicles, such as liposomes [25]. Cavitation therefore, appears to
play two roles: it disrupts the structure of the carrier vesicle and releases the drug, but it also makes
cell membranes and capillaries more permeable to drugs. In a study by Dong et al. [26], microbubbles
were injected subcutaneously, in order to increase US cavitation, into an in vivo rabbit model into
which two Staphylococcus epidermidis infected catheters had previously been implanted. The animal
group that was treated with vancomycin, US (300 kHz, 0.5 W/cm−2, 50% duty cycle) and microbubbles
was compared to the control group and other animal groups. The antibacterial activity of vancomycin
against Staphylococcus epidermidis biofilms was found to be enhanced by three orders of magnitude,
compared to the control, confirming that US cavitation can play an important role against infections,
especially against these communities of microorganisms that can attach to both abiotic and biotic
surfaces [27]. Biofilms consist of microorganisms with altered phenotypes that live in a self-organised,
cooperative community that is attached to surfaces and each other and embedded into a self-produced
matrix of exopolymer saccharides. Biofilms are relevant for home care and hospice clinicians because
the colonisation of medical devices plays a key role in the issue of healthcare-associated infections [28].
In another work [29], the authors showed that the focused US and gentamicin-encapsulated
liposomes reduced the number of viable bacteria in alginate-based Ralstonia insidiosa biofilms by
approximately 72%, compared to US alone, gentamicin in solution alone (no liposomes) and gentamicin
in solution with high-intensity focused US. These data show that high-intensity focused US in
combination with an antibiotic strategy can kill bacteria within synthetic alginate biofilms, while
non-focused US was able to increase the attachment of liposomes to the biofilm, as demonstrated by
the same authors [30].
2.1.3. Magnetothermal Release
The magnetothermally stimulated release of antibiotics from drug-delivery vehicles has been
demonstrated using superparamagnetic iron oxide nanoparticles (SPIONs) [31–34]. SPIONs consist of
cores made of iron oxides that can be targeted to the required area using external magnets. SPIONs
exhibit a range of favourable properties, including intrinsic magnetism for MRI, safety and the
availability of biocompatible coatings and surface functional moieties. These features opened up a
wide range of possible applications for SPIONs in drug delivery [35], in vivo medical imaging [36],
biosensing [37], regenerative medicine [38] and hyperthermia [39]. SPION-based DDSs are commonly
composed of magnetite and maghemite NPs with an organic or inorganic coating. These magnetic
drug-bearing nanostructures rely on external magnetic-field guidance to reach their target tissue.
Magnetic vehicles, including magnetic capsules, magnetoliposomes and magnetodendrimers reduce
the clearance of drugs and increase their blood-circulation time. They also increase drug-internalisation
efficiency in target cells and minimise nonspecific cellular interactions, thus reducing the total required
dose and associated side effects. Their unique superparamagnetic characteristics mean that SPIONs
become magnetised up to their saturation magnetisation, using an external magnetic field, and gain
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high magnetic susceptibility. No magnetic interaction is observed upon the removal of the magnetic
field. In this way, SPIONs acquire the capability to transport the encapsulated or attached drug to the
target site in the body under an applied magnetic field and are inactivated upon the removal of the
magnetic field [40].
In this regard, Mohapatra and colleagues used chitosan-based microbeads that were loaded
with magnetite SPIONs to demonstrate the on-demand release of vancomycin [34]. In this system,
the SPIONs were incorporated during the microbead formation, which involves the cross-linking of
chitosan and vancomycin to poly(ethylene glycol) dimethacrylate (PEGDMA). Following the exposure
of the SPION-loaded microbeads to a 25 mT alternating magnetic field (AMF) at 109.9 kHz for 30 min,
the generation of localised magnetothermal heating, three, five and seven hours from the start of
the experiment, provided sufficient energy to cleave the ester bonds linking the vancomycin to the
microbeads. This resulted in a significantly higher amount of vancomycin being released from the
microbeads, to levels above the minimum inhibitory concentration (MIC), than those that were released
by the non-stimulated control, which remained below the MIC. To further confirm the suitability of this
approach to the antimicrobial field, Sirivisoot and co-workers [32], presented the release of ciprofloxacin,
which was encapsulated within polycaprolactone-iron-oxide NPs after exposure to an alternating
magnetic field for 1 day, in a Staphylococcus aureus broth inhibition assay. The authors also pointed
out that the magnetothermal response of a SPION may differ from one iron oxide form to another.
Indeed, the co-loading of either maghemite or hematite NPs with ciprofloxacin in polycaprolactone
microspheres exhibited differences in the release and also in the bactericidal efficacy of ciprofloxacin
against Staphylococcus aureus after exposure to an alternating magnetic field. Higher release and efficacy
was observed in the maghemite-loaded microspheres than in the hematite-loaded microspheres.
2.2. Magnetic Release
The superparamagnetic properties of SPION might also be an ideal way to promote the release,
upon the use of an external magnetic field, of antibiotics in unique bacteria microenvironments, such
as a biofilm, where highly dynamic communities of immobile bacteria and a protective extracellular
polymeric matrix provide the conditions for the development of innate resistance to both antimicrobial
compounds and host-response factors. Geilich et al. [41], demonstrated the biofilm-eradication
effectiveness of this method using iron oxide polymersome (IOPs) formed from methoxy poly(ethylene
glycol)-b-poly(d,l-lactic acid) diblock co-polymers to co-encapsulate methicillin within the aqueous
core and hydrophobic SPIONs within the membrane bilayer. In this work, biofilms formed from
Staphylococcus epidermidis were grown on glass cover slips and incubated with IOPs containing
20–100 µg mL−1 of SPIONs and 10–50 µg mL−1 methicillin for 24 h. A magnetic field was subsequently
used to pull the IOPs through the biofilm. The application of the IOPs and the magnetic field to the
biofilm resulted in the effective penetration of the IOPs through the biofilm and a selective bactericidal
effect within the region of the applied magnetic field. Importantly, complete biofilm eradication was
observed using IOPs that contained SPIONs and methicillin at a lower concentration than the minimum
bactericidal concentration (MBC) value of free methicillin for Staphylococcus epidermidis grown within
a biofilm.
3. Endogenous Stimuli-Responsive Antibiotic Drug-Delivery Systems
pH variation has been exploited to control the delivery of drugs to specific organs (i.e.,
the gastrointestinal tract or the vagina) and intracellular compartments (such as endosomes or
lysosomes), and to trigger the release of the drug when subtle environmental changes are associated
with pathological situations, such as cancer or infection. Two main strategies exist: (i) the use
of polymers (polyacids or polybases) with ionisable groups that undergo conformational and/or
solubility changes in response to environmental pH variation; (ii) the design of polymeric systems
with acid-sensitive bonds whose cleavage enables the release of molecules that are anchored to the
polymer backbone [12].
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In this regard, Radovic-Moreno and colleagues [42], developed
vancomycin-encapsulated, pH-responsive, surface charge-switching poly(d,l-lactic-co-glycolic
acid)-b-poly(l-histidine)-b-poly(ethylene glycol) nanoparticles for the treatment of Staphylococcus
aureus infection. The results suggest that the promotion of NP-bacteria interactions under acidic
conditions can partially mitigate the loss of vancomycin activity with pH, which highlights the
potential of this drug-delivery system for the treatment of infections that are associated with localised
acidity. Furthermore, pH responsiveness has also been used in the treatment of resistant intracellular
infections as bacteria are located in acidic intracellular compartments. Sémiramoth and co-workers [43],
described innovative nanoparticles that are based on the bioconjugation of penicillin G (PNG) to
squalene (SqPNG) and that are designed to release penicillin G within acidic subcellular organelles
(SqPNG-pH), such as lysosomes, in order to overcome severe intracellular infections by pathogens
whose mechanisms of resistance arise from the poor intracellular diffusion of a range of antibiotics.
The antibacterial activity of SqPNG-pH NPs was investigated against Staphylococcus aureus, which is
able to invade and survive in macrophages. The data clearly show that SqPNG-pH NPs present a
significant ability to kill intracellular Staphylococcus aureus (87% inactivation) compared to with all
the other treatments, i.e., free PNG or SqPNG NPs. Kalhapure and colleagues [44], have recently
synthesised a new lipid with a cleavable acetal linkage as part of their development of pH-responsive
solid lipid nanoparticles (SLNs) that can more specifically deliver vancomycin in an acidic environment
to control the growth of methicillin-sensitive Staphylococcus aureus (MSSA) and MRSA.
Hydrogels are a class of highly hydrated biomaterials that are usually produced from natural
or synthetic polymers. Many hydrogels are biocompatible and can be designed to have mechanical
properties similar to natural tissues, and thus have been used in a myriad of applications including
drug delivery [45]. Their hydrophilic nature means that some antibiotics, such as ciprofloxacin [46–48]
and vancomycin [49], have been used to prepare active gels. Although these carriers were able to
provide the controlled release of antimicrobial agents and had good antibacterial activity, the release
profiles from these carriers were found to be load-dependent and time-dependent and to lack the
ability to respond smartly to the microenvironment of the bacterial infection. pH-responsive antibiotic
delivery systems have therefore gained considerable attention thanks to their enormous potential and
ease of application in the clinical treatment of infections, such as the eradication of Helicobacter pylori,
for which antibiotics need to penetrate the gastric mucus layer and maintain a concentration sufficient
for antibacterial activity in the infected site for a suitable length of time. In order to tackle this issue,
Chang et al. [50], developed a pH-sensitive hydrogel that incorporate chitosan/γPGA NPs that are
loaded with amoxicillin. They investigated the physicochemical characteristics of the hydrogels and
nanoparticles as a function of pH values in a human gastric adenocarcinoma cell line and at the site of
Helicobacter pylori infection. They found that the system protects the drug from destruction by gastric
acid, and that the amoxicillin interacted specifically with the intercellular spaces and with the cell
cytoplasm of the site of Helicobacter pylori infection. In a broader antimicrobial context, pH-responsive
hydrogels may well be used as controlled-release systems to treat a range of different infections. Lu and
colleagues [51], designed a pH-sensitive poly(acrylic acid) (PAA) and p-(2-(dimethylamino)ethyl
methacrylate) (PDMAEMA) composite hydrogel. The hydrogel decomposed gradually when placed
in a weak acidic microenvironment, but was stable under normal physiological and weakly basic
environments. The authors investigated the in vitro release rates of vancomycin and levofloxacin from
the hydrogel using a UV spectrophotometer at a number of pH values (5.5, 7.3 and 9.1). Both drugs
were completely released at pH 5.5 due to the degradation of the hydrogel under these acidic conditions.
The antibacterial activity of vancomycin-loaded hydrogel provided decreased Staphylococcus aureus
proliferation activity in 4 h, and 99% of the bacteria was killed after 6 h. A similar approach was
proposed by Anirudhan et al. [52]. In their work, gentamicin (GS), ampicillin (Amp) and 2-amino
guanidine, which was used to limit the side effects of GS, were encapsulated in a pH sensitive
gelatin methacrylate/methacrylic acid hydrogel. Swelling and drug-release studies confirms that the
external pH was the triggering force for the release of the drugs, while in vitro antimicrobial studies
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against Escherichia coli and Staphylococcus aureus confirmed the increased antibacterial effect of the
drug combination.
pH-sensitive liposomes have been extensively used as an alternative to conventional
liposomes for the intracellular delivery of therapeutics/antigen/DNA/diagnostics to various target-cell
compartments [53]. A number of researchers have suggested a range of strategies for the use of
pH-sensitive liposomes in the antimicrobial field. Lutwyche and colleagues [54], encapsulated
gentamicin in a pH-sensitive liposomal formulation and characterised its delivery to Salmonella
typhimurium and Listeria monocytogenes, which resided in cultured macrophages. More recently,
the same authors [55], investigated the same formulation in vivo in a mouse model that bore a
systemic Salmonella enterica serovar typhimurium infection. The study showed that the encapsulation of
gentamicin in pH-sensitive liposomes significantly increased the concentrations of the drug in plasma,
the liver and spleen, compared to those of free gentamicin in the murine salmonellosis model, and
that the antibacterial activity was 104-fold higher than for free gentamicin. A similar approach, but
against a basidiomycetous yeast that causes serious infections of the lungs and central nervous system
in immunocompromised patients, was introduced by Nasti et al. [56]. The authors evaluated the
efficacy of pH-sensitive liposomes of nystatin against Cryptococcus neoformans infection in a murine
model. They found that the use of pH-sensitive liposomes significantly enhanced the intracellular
delivery of nystatin, and showed enhanced antifungal activity, in terms of increased survival rate,
while fungal burden in brain and liver was reduced. Furthermore, significant nystatin toxic effects,
which were observed in the free form, were avoided. As previously described, although liposomes
have been extensively studied as antimicrobial delivery vehicles and present proven advantageous
features (i.e., high biocompatibility, unique bilayer structure that can fuse with bacterial membranes,
high drug-carrying capacity and readily tunable formulation properties), their applications are often
limited by poor stability, which is caused by spontaneous fusion among liposomes, leading to payload
loss and non-reproducible mixing. Several attempts have been made to overcome these drawbacks by
coating their surface with a stealth material such as polyethylene glycol (PEG) [57,58], and zwitterionic
polymers [59], but these liposomes are rarely used for antimicrobial delivery to treat bacterial infections.
This is mainly due to the fact that the polymer coating not only stabilises the liposomes against
fusion with each other, but also prevents them from fusing with bacterial membranes across which
the antimicrobial payload must be delivered. The engineering of liposomal formulations that are
stabilised against fusion prior to arriving at target bacteria, while maintaining their ability to fuse with
cell membranes at the infection sites would be the ideal situation. In this regard, Thamphiwatana
and co-workers [60], have developed negatively charged doxycycline-loaded liposomes that are
electrostatically stabilised with small cationic chitosan-coated Au NPs for the gastric delivery of
antibiotics to treat Helicobacter pylori infections. The authors demonstrated that, at acidic pH, the
chitosan coating on the Au NPs is predominantly protonated, thus enabling strong binding to the
liposomes and promoting their stabilisation via electrostatic repulsions between the Au NP-coated
liposomes. However, the deprotonation of the chitosan coating on the Au NPs occurs at neutral pH,
leading to the detachment of the Au NPs from the liposomes and to the latters’ subsequent fusion with
a bacterial membrane, which releases the encapsulated doxycycline to eradicate the bacteria. Indeed,
the authors demonstrated that their system had superior antibacterial efficacy against Helicobacter
pylori than the same concentrations of free doxycycline.
Finally for this field, micelles have demonstrated several attractive advantages over other types of
carriers; higher stability than liposomes and stronger responsiveness to stimuli than nanoparticles.
Indeed, the hydrophilic outer corona of a micelle is able to reduce the uptake by the reticuloendothelial
system, prolonging in vivo circulation, whereas their hydrophobic inner core is beneficial for the
high-capacity loading of poorly water-soluble chemical compounds, such as antibiotics. Chen et al. [61],
therefore developed a novel pH and lipase-sensitive vancomycin (Van)-hydrazone-poly(ethylene
glycol)-poly(ε-caprolactone)/ciprofloxacin (Cip) micelles (Van-hyd-PECL/Cip) to achieve bacterial
targeting using an antibiotic (Van) and the on-demand release of antibiotics (Van and Cip) to combat
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bacterial infections. Their results included the higher survival of Pseudomonas aeruginosa-infected mice,
lower bacterial burden and decreased alveolar injuries in the lungs, compared with micelles used
without the inoculation of Van moieties, and free drugs. Triple doses of Van-hyd-PECL/Cip micelles
further extend animal survival, decrease the bacterial colonisation of the lungs and almost completely
restored normal alveolar microstructure.
4. Antibiotic Nanoparticles
Antibiotic drug-delivery systems and antibiotic stimuli-response drug-delivery systems,
as previously described, offer undoubted advantages, in terms of resistance and side effects, compared
to conventional antibiotics. However, translation to the clinic is still beyond reach for most approaches.
Only liposomes and lipid nanoparticles for amphotericin delivery, including Abelcet®, Amphotec®,
Ambisome®, and Arikayce®, are currently approved for use in patients. The identification of novel
and efficient antimicrobial therapies therefore still remains a priority in the war against infections.
The use of nanoantibiotics (nAbts) as a therapeutic strategy has recently gained a lot of attention [62,63].
nAtbs are nanomaterials that have antimicrobial activity or improve the efficacy and safety of
antibiotic administration [64]. nAbts have many advantages over conventional antibiotics, including
production, storage, durability and versatility, while preparation may also be cheaper, faster and
more adaptable, with the added advantage of a long shelf-life. Compared to conventional antibiotic
drug-delivery systems, nAbts show higher surface-area-to-volume ratios and unique chemical-physical
properties. They are typically composed of either naturally occurring antibacterial substances, metals
and metal oxides, carbon-based nanomaterials, or nanoemulsions. Some authors have proposed that
the antimicrobial mechanisms of nAbts include the generation of reactive oxygen species (ROS) as
reported by Dai and colleagues in their research work [65] (Figure 2), the disruption/compromising
of the bacterial cell wall/membrane, the interruption of energy transduction and the inhibition of
enzyme activity and DNA synthesis [66]. Although some mechanisms appear to overlap with those
of conventional antibiotics, the actual mechanisms by which these occur are vastly different; nAbts
physically disrupt key biological process, while conventional antibiotics interfere on the molecular scale.
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nAtbs come in a range of chemical compositions, shapes and sizes, and their chemical-physical
versatility clearly indicates that there is a synergistic opportunity to be taken in designing nAbts
with a stimuli-responsive linker [66], such as those for temperature, light, pH, redox and enzymes.
In this regard, interesting are the antimicrobial strategies called “photoantimicrobial chemotherapy”
(PACT) and “sonoantimicrobial chemotherapy” (SACT) [67]. These approaches, similar to photo-
and sonodynamic therapy [68,69], rely on two individually harmless components, i.e., a sensitiser
and a physical trigger as light or US. The irradiation of the sensitiser with light or US initiates
a chain of events that culminates with the production of highly reactive cytotoxic species, which
rapidly lead to bacteria death. The combination of photoirradiation and sensitiser exposure has
been reported as a potential bactericidal approach. In a work by Dhal et al., the authors used a
combination of photodynamic exposure and rose bengal on several Gram-positive species (Bacillus
subtilis, Staphylococcus aureus, Streptococcus faecalis and Streptococcus salivarius) and Gram-negative
Salmonella typhimurium. They observed a 99% inactivation of Gram-positive bacterial species, as
compared to Salmonella typhimurium. This led to the hypothesis the mechanism of rose bengal anion
penetration through the outer portion of the Gram-negative cell wall to a critical location within the cell
for effective photosensitisation is effectively different [70]. Recently, a study by Sabbahi and colleagues
reported the antimicrobial activity of dianionic rose bengal disodium salt, under photodynamic
exposure, on Staphylococcus aureus. The synergism between photosensiser and light exposure induced
a 79.4% reduction in bacterial viability. Specifically, hydroxyl radicals played the most important role
in the photoinactivation of the tested bacteria by the dianionic rose bengal [71].
A few examples of the antimicrobial roles of nAtbs under stimuli response will be reported
herein (Table 1). Nitric oxide shows some potential antimicrobial activity thanks to its cytotoxic effect,
which is associated with radical species production. Specifically, Consoli and colleagues described the
antibacterial activity of a calixarene-NO donor conjugate, when exposed to light treatment, towards
Staphylococcus aureus and Escherichia coli, which were chosen as representatives of the Gram-positive
and Gram-negative bacteria strains [72]. Using calixarene as cages for the storage and release of
gaseous NO, a significant biocidal effect towards Staphylococcus aureus count was observed upon
visible light irradiation, in an irradiation-time dependent fashion. The same effect was not observed
on Escherichia coli, and it was thought that this was because of the different way the Gram-negative
bacteria are organised. Therefore, an interesting photoresponsive effect was provided by calixarene-NO
complex [72].
Table 1. Examples of stimuli-responsive nanoantibiotics (nAtbs).
Type Average NPDiameter Stimulus
Mechanism of
Antibacterial Action Application Reference
Calixarene-NO
donor conjugate 270 nm Light (400 nm)
Damage of cell
membrane by NO
release
S. aureus, E. coli [70]
Nanogel of aniline
and
chitosan-containing
Ag NPs
78 nm Light (405 nm)
Damage of cell
membrane by Ag NP
release
E. coli [71]
Ni-TiO2 NPs 10 nm Light (400 nm)
Damages of cell
membrane by ROS
generation
S. aureus, B. subtilis,
E. coli and S. abony [72]
A further interesting antimicrobial strategy is the use of metallic nanoparticles, such as Ag NPs [73];
whereas synergic activity between silver ions release and hyperthermia caused by the photo-thermal
effect under near-infrared laser irradiation occurs [74–76]. In this regard in a work by Ballesteros,
the authors reported the use of nanogels that were loaded with metallic nanoparticles and presented the
synergic activity of this platform after irradiation with a specific wavelength. This irradiation generates
local electronic vibrations which lead to changes in polymeric structure, releasing the nanoparticles
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into the surrounding environment. Silver nanoparticles stand out from other nanoparticles that
display antibacterial properties as the silver ions that are released from the crystalline core can produce
chemical disequilibrium in bacterial cells. Ballesteros and colleagues demonstrated that the irradiation
of a nanogel at 405 nm induces the excitation of Ag NPs and thus the rupture of cross-linking, leading
to its release over time. In this context, the kinetics of Ag NP release under irradiation with a 405 nm
diode LED was investigated in Gram-negative Escherichia coli [77].
A great amount of information, which has been accumulated over the last 20 years, has
demonstrated the strong bactericidal activity of titanium dioxide (TiO2), which is a commonly
used semiconductor photocatalyst, upon irradiation with near-UV light and UVA. The required
concentration for bacteria-killing varies over the 100–1000 ppm range, depending on TiO2 NP size and
the intensity and wavelength of the light, although it has been mainly attributed to the production
of free-hydroxyl radicals and peroxide [62]. A new study by Yadav and colleagues has reported that
the antibacterial efficiency of Ni-TiO2 NPs under light exposure is higher towards Gram-positive
Staphylococcus aureus and Bacillus subtilis, than towards Gram-negative Escherichia coli and Salmonella
abony, which is seemingly determined by the complexity and the density of the cell membrane/wall [78].
5. Conclusions
The use of stimuli-responsive nanoparticles shows great promise as it may provide long-term
solution to the main drawbacks in antimicrobial therapy: resistance and the severity of side effects.
One of the major advantages provided by this approach is the spatial and temporal release of antibiotics
from drug carriers at an infection site. This is achieved by photo, magneto, thermal, US and pH
stimuli, whereas stimuli-responsive nAbt systems allow traditional antibiotic discovery pathways to be
bypassed. Moreover, the therapeutic relevance in this field is confirmed by the role in other fields such as
cancer treatment, vaccine development and theranostic applications. In particular, this approach seems
better than existing due to the controlled and precise delivery of the antibacterial agents improving the
therapeutic effect mainly on abscesses and infected wounds, with a reduction of systemic side-effects.
Furthermore inorganic NPs, by external stimuli, can also improve penetration of antibiotics through
difficult-to-treat biofilms as seen with SPIONs and Ag NPs. Regarding the manufacturing aspect,
surely inorganic NP can be preferred as they can confer stimuli-responsive properties in a simpler and
more reproducible manner. However, while promising in vitro antibacterial effects have been observed,
these novel systems are still in the relatively early stages of development and certain challenges
associated with the use of different types of nAbts and stimuli-responsive drug-delivery systems for
the release of antibiotics exist and still need to be overcome. These include technology limitations
in providing a stimulus to nAbts or delivery systems. For example, the limited tissue-penetration
depth of light can restrict its application to superficial infections even though the near-infrared laser
irradiation could overcome this issue due to a greater penetration depth. Furthermore, the need for
the co-development of a cost-effective magnetic-field generator that is suitable for use against a range
of infection types is an issue in the case of the magnetic-based systems. Crucially, the toxicity of the
materials, especially inorganic materials, remains a challenge. However, a systematic method that
address these challenges may well pave the way for innovative therapeutic avenues without end.
Author Contributions: Conceptualization, R.C.; L.S.; writing—original draft preparation, R.C. and F.F.;
writing—review and editing, C.D.P., F.D., F.G. and L.S.
Funding: This research was funded by the University of Torino (grant “Ricerca Locale 2018”).
Acknowledgments: The Authors would like to thank Dale Lawson for his critical appraisal of the manuscript
and advice.
Conflicts of Interest: All of the authors declare no conflict of interest.
Molecules 2019, 24, 1991 12 of 15
References
1. Antibiotic Resistance. Available online: https://www.who.int/news-room/fact-sheets/detail/antibiotic-
resistance (accessed on 15 February 2019).
2. Zhu, X.; Radovic-Moreno, A.F.; Wu, J.; Langer, R.; Shi, J. Nanomedicine in the management of microbial
infection—Overview and perspectives. Nano Today 2014, 9, 478–498. [CrossRef]
3. Briones, E.; Isabel Colino, C.; Lanao, J.M. Delivery systems to increase the selectivity of antibiotics in
phagocytic cells. J. Control. Release 2008, 125, 210–227. [CrossRef] [PubMed]
4. Zhang, L.; Pornpattananangku, D.; Hu, C.-M.J.; Huang, C.-M. Development of nanoparticles for antimicrobial
drug delivery. Curr. Med. Chem. 2010, 17, 585–594. [CrossRef] [PubMed]
5. Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal Formulations in Clinical Use: An
Updated Review. Pharmaceutics 2017, 9, 12. [CrossRef]
6. Bozzuto, G.; Molinari, A. Liposomes as nanomedical devices. Int. J. Nanomed. 2015, 10, 975–999. [CrossRef]
[PubMed]
7. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine:
Therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83, 761–769. [CrossRef]
8. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4,
145–160. [CrossRef] [PubMed]
9. Liposomes as a Drug Delivery System | Biological and Pharmaceutical Applications of Nanomaterials |
Taylor & Francis Group. Available online: https://www.taylorfrancis.com/ (accessed on 26 April 2019).
10. Munita, J.M.; Arias, C.A. Mechanisms of Antibiotic Resistance. Microbiol. Spectr. 2016, 4.
11. Yatvin, M.B.; Weinstein, J.N.; Dennis, W.H.; Blumenthal, R. Design of liposomes for enhanced local release of
drugs by hyperthermia. Science 1978, 202, 1290–1293. [CrossRef] [PubMed]
12. Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12,
991–1003. [CrossRef] [PubMed]
13. Moorcroft, S.C.T.; Jayne, D.G.; Evans, S.D.; Ong, Z.Y. Stimuli-Responsive Release of Antimicrobials Using
Hybrid Inorganic Nanoparticle-Associated Drug-Delivery Systems. Macromol. Biosci. 2018, 18, 1800207.
[CrossRef] [PubMed]
14. Meeker, D.G.; Jenkins, S.V.; Miller, E.K.; Beenken, K.E.; Loughran, A.J.; Powless, A.; Muldoon, T.J.;
Galanzha, E.I.; Zharov, V.P.; Smeltzer, M.S.; et al. Synergistic Photothermal and Antibiotic Killing
of Biofilm-Associated Staphylococcus aureus Using Targeted Antibiotic-Loaded Gold Nanoconstructs.
ACS Infect. Dis. 2016, 2, 241–250. [CrossRef]
15. Jaque, D.; Martínez Maestro, L.; del Rosal, B.; Haro-Gonzalez, P.; Benayas, A.; Plaza, J.L.; Martín Rodríguez, E.;
García Solé, J. Nanoparticles for photothermal therapies. Nanoscale 2014, 6, 9494–9530. [CrossRef]
16. Kahn, S.A.; Singh, A.K.; Senapati, D.; Fan, Z.; Ray, P.C. Bio-conjugated popcorn shaped gold nanoparticles
for targeted photothermal killing of multiple drug resitant Salmonella DT104. J. Mater. Chem. 2011, 21,
17705–17709. [CrossRef]
17. Radt, B.; Smith, T.A.; Caruso, F. Optically Addressable Nanostructured Capsules. Adv. Mater. 2004, 16,
2184–2189. [CrossRef]
18. Amoli-Diva, M.; Sadighi-Bonabi, R.; Pourghazi, K. Laser-assisted triggered-drug release from silver
nanoparticles-grafted dual-responsive polymer. Mater. Sci. Eng. C Mater. Biol. Appl. 2017, 76, 536–542.
[CrossRef]
19. Liu, M.; He, D.; Yang, T.; Liu, W.; Mao, L.; Zhu, Y.; Wu, J.; Luo, G.; Deng, J. An efficient antimicrobial depot
for infectious site-targeted chemo-photothermal therapy. J. Nanobiotechnol. 2018, 16, 23. [CrossRef]
20. Borzenkov, M.; Moros, M.; Tortiglione, C.; Bertoldi, S.; Contessi, N.; Faré, S.; Taglietti, A.; D’Agostino, A.;
Pallavicini, P.; Collini, M.; et al. Fabrication of photothermally active poly(vinyl alcohol) films with gold
nanostars for antibacterial applications. Beilstein J. Nanotechnol. 2018, 9, 2040–2048. [CrossRef] [PubMed]
21. Amstad, E.; Kim, S.-H.; Weitz, D.A. Photo- and thermoresponsive polymersomes for triggered release. Angew.
Chem. Int. Ed Engl. 2012, 51, 12499–12503. [CrossRef] [PubMed]
22. Leung, S.J.; Kachur, X.M.; Bobnick, M.C.; Romanowski, M. Wavelength-Selective Light-Induced Release from
Plasmon Resonant Liposomes. Adv. Funct. Mater. 2011, 21, 1113–1121. [CrossRef] [PubMed]
Molecules 2019, 24, 1991 13 of 15
23. Wu, G.; Mikhailovsky, A.; Khant, H.A.; Fu, C.; Chiu, W.; Zasadzinski, J.A. Remotely triggered liposome
release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc. 2008, 130, 8175–8177.
[CrossRef]
24. Husseini, G.A.; Diaz de la Rosa, M.A.; Richardson, E.S.; Christensen, D.A.; Pitt, W.G. The role of cavitation in
acoustically activated drug delivery. J. Control. Release 2005, 107, 253–261. [CrossRef]
25. Pitt, W.G.; Husseini, G.A.; Staples, B.J. Ultrasonic Drug Delivery – A General Review. Expert Opin. Drug
Deliv. 2004, 1, 37–56. [CrossRef]
26. Dong, Y.; Li, J.; Li, P.; Yu, J. Ultrasound Microbubbles Enhance the Activity of Vancomycin Against
Staphylococcus epidermidis Biofilms In Vivo. J. Ultrasound Med. Off. J. Am. Inst. Ultrasound Med. 2018, 37,
1379–1387. [CrossRef]
27. Percival, S.L.; Suleman, L.; Vuotto, C.; Donelli, G. Healthcare-associated infections, medical devices and
biofilms: Risk, tolerance and control. J. Med. Microbiol. 2015, 64, 323–334. [CrossRef]
28. Talsma, S.S. Biofilms on medical devices. Home Healthc. Nurse. 2007, 25, 589–594. [CrossRef]
29. Ma, D.; Wu, J. Biofilm mitigation by drug (gentamicin)-loaded liposomes promoted by pulsed ultrasound.
J. Acoust. Soc. Am. 2016, 140, EL534–EL538. [CrossRef]
30. Ma, D.; Green, A.M.; Willsey, G.G.; Marshall, J.S.; Wargo, M.J.; Wu, J. Effects of acoustic streaming
from moderate-intensity pulsed ultrasound for enhancing biofilm mitigation effectiveness of drug-loaded
liposomes. J. Acoust. Soc. Am. 2015, 138, 1043–1051. [CrossRef]
31. Mahmoudi, M.; Sant, S.; Wang, B.; Laurent, S.; Sen, T. Superparamagnetic iron oxide nanoparticles (SPIONs):
Development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 2011, 63, 24–46.
[CrossRef]
32. Sirivisoot, S.; Harrison, B.S. Magnetically stimulated ciprofloxacin release from polymeric microspheres
entrapping iron oxide nanoparticles. Int. J. Nanomed. 2015, 10, 4447–4458. [CrossRef]
33. Harris, M.; Ahmed, H.; Barr, B.; LeVine, D.; Pace, L.; Mohapatra, A.; Morshed, B.; Bumgardner, J.D.;
Jennings, J.A. Magnetic stimuli-responsive chitosan-based drug delivery biocomposite for multiple triggered
release. Int. J. Biol. Macromol. 2017, 104, 1407–1414. [CrossRef]
34. Mohapatra, A.; Harris, M.A.; LeVine, D.; Ghimire, M.; Jennings, J.A.; Morshed, B.I.; Haggard, W.O.;
Bumgardner, J.D.; Mishra, S.R.; Fujiwara, T. Magnetic stimulus responsive vancomycin drug delivery system
based on chitosan microbeads embedded with magnetic nanoparticles. J. Biomed. Mater. Res. B Appl. Biomater.
2018, 106, 2169–2176. [CrossRef]
35. Durán, J.D.G.; Arias, J.L.; Gallardo, V.; Delgado, A.V. Magnetic colloids as drug vehicles. J. Pharm. Sci. 2008,
97, 2948–2983. [CrossRef]
36. Corot, C.; Robert, P.; Idée, J.-M.; Port, M. Recent advances in iron oxide nanocrystal technology for medical
imaging. Adv. Drug Deliv. Rev. 2006, 58, 1471–1504. [CrossRef]
37. Saei, A.A.; Dolatabadi, J.E.N.; Najafi-Marandi, P.; Abhari, A.; de la Guardia, M. Electrochemical biosensors
for glucose based on metal nanoparticles. TrAC Trends Anal. Chem. 2013, 42, 216–227. [CrossRef]
38. Mahmoudi, M.; Hosseinkhani, H.; Hosseinkhani, M.; Boutry, S.; Simchi, A.; Journeay, W.S.; Subramani, K.;
Laurent, S. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a
tool for the advancement of clinical regenerative medicine. Chem. Rev. 2011, 111, 253–280. [CrossRef]
39. Laurent, S.; Dutz, S.; Häfeli, U.O.; Mahmoudi, M. Magnetic fluid hyperthermia: Focus on superparamagnetic
iron oxide nanoparticles. Adv. Colloid Interface Sci. 2011, 166, 8–23. [CrossRef]
40. Laurent, S.; Saei, A.A.; Behzadi, S.; Panahifar, A.; Mahmoudi, M. Superparamagnetic iron oxide nanoparticles
for delivery of therapeutic agents: Opportunities and challenges. Expert Opin. DrugDeliv. 2014, 11, 1449–1470.
[CrossRef]
41. Geilich, B.M.; Gelfat, I.; Sridhar, S.; van de Ven, A.L.; Webster, T.J. Superparamagnetic iron oxide-encapsulating
polymersome nanocarriers for biofilm eradication. Biomaterials 2017, 119, 78–85. [CrossRef]
42. Radovic-Moreno, A.F.; Lu, T.K.; Puscasu, V.A.; Yoon, C.J.; Langer, R.; Farokhzad, O.C. Surface
charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano
2012, 6, 4279–4287. [CrossRef]
43. Sémiramoth, N.; Di Meo, C.; Zouhiri, F.; Saïd-Hassane, F.; Valetti, S.; Gorges, R.; Nicolas, V.; Poupaert, J.H.;
Chollet-Martin, S.; Desmaële, D.; et al. Self-assembled squalenoylated penicillin bioconjugates: An original
approach for the treatment of intracellular infections. ACS Nano 2012, 6, 3820–3831. [CrossRef]
Molecules 2019, 24, 1991 14 of 15
44. Kalhapure, R.S.; Sikwal, D.R.; Rambharose, S.; Mocktar, C.; Singh, S.; Bester, L.; Oh, J.K.; Renukuntla, J.;
Govender, T. Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid
cleavable lipid. Nanomed. Nanotechnol. Biol. Med. 2017, 13, 2067–2077. [CrossRef]
45. Veiga, A.S.; Schneider, J.P. Antimicrobial hydrogels for the treatment of infection. Biopolymers 2013, 100,
637–644. [CrossRef]
46. Tsou, T.-L.; Tang, S.-T.; Huang, Y.-C.; Wu, J.-R.; Young, J.-J.; Wang, H.-J. Poly(2-hydroxyethyl methacrylate)
wound dressing containing ciprofloxacin and its drug release studies. J. Mater. Sci. Mater. Med. 2005, 16,
95–100. [CrossRef]
47. De Giglio, E.; Cometa, S.; Ricci, M.A.; Cafagna, D.; Savino, A.M.; Sabbatini, L.; Orciani, M.; Ceci, E.;
Novello, L.; Tantillo, G.M.; et al. Ciprofloxacin-modified electrosynthesized hydrogel coatings to prevent
titanium-implant-associated infections. Acta Biomater. 2011, 7, 882–891. [CrossRef]
48. Marchesan, S.; Qu, Y.; Waddington, L.J.; Easton, C.D.; Glattauer, V.; Lithgow, T.J.; McLean, K.M.; Forsythe, J.S.;
Hartley, P.G. Self-assembly of ciprofloxacin and a tripeptide into an antimicrobial nanostructured hydrogel.
Biomaterials 2013, 34, 3678–3687. [CrossRef]
49. Bhattacharyya, S.; Agrawal, A.; Knabe, C.; Ducheyne, P. Sol-gel silica controlled release thin films for the
inhibition of methicillin-resistant Staphylococcus aureus. Biomaterials 2014, 35, 509–517. [CrossRef]
50. Chang, C.-H.; Lin, Y.-H.; Yeh, C.-L.; Chen, Y.-C.; Chiou, S.-F.; Hsu, Y.-M.; Chen, Y.-S.; Wang, C.-C. Nanoparticles
incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori.
Biomacromolecules 2010, 11, 133–142. [CrossRef]
51. Lu, Z.; Zhang, J.; Yu, Z.; Liu, Q.; Liu, K.; Li, M.; Wang, D. Hydrogel degradation triggered by pH for the
smart release of antibiotics to combat bacterial infection. New J. Chem. 2017, 41, 432–436. [CrossRef]
52. Anirudhan, T.S.; Mohan, A.M. Novel pH sensitive dual drug loaded-gelatin methacrylate/methacrylic acid
hydrogel for the controlled release of antibiotics. Int. J. Biol. Macromol. 2018, 110, 167–178. [CrossRef]
53. Paliwal, S.R.; Paliwal, R.; Vyas, S.P. A review of mechanistic insight and application of pH-sensitive liposomes
in drug delivery. Drug Deliv. 2015, 22, 231–242. [CrossRef]
54. Lutwyche, P.; Cordeiro, C.; Wiseman, D.J.; St-Louis, M.; Uh, M.; Hope, M.J.; Webb, M.S.; Finlay, B.B.
Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes.
Antimicrob. Agents Chemother. 1998, 42, 2511–2520. [CrossRef]
55. Cordeiro, C.; Wiseman, D.J.; Lutwyche, P.; Uh, M.; Evans, J.C.; Finlay, B.B.; Webb, M.S. Antibacterial Efficacy
of Gentamicin Encapsulated in pH-Sensitive Liposomes against an In Vivo Salmonella enterica Serovar
Typhimurium Intracellular Infection Model. Antimicrob. Agents Chemother. 2000, 44, 533–539. [CrossRef]
56. Nasti, T.H.; Khan, M.A.; Owais, M. Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus
neoformans in murine model. J. Antimicrob. Chemother. 2006, 57, 349–352. [CrossRef]
57. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U.S. Poly(ethylene glycol) in drug delivery: Pros and cons
as well as potential alternatives. Angew. Chem. Int. Ed Engl. 2010, 49, 6288–6308. [CrossRef]
58. Stepniewski, M.; Pasenkiewicz-Gierula, M.; Róg, T.; Danne, R.; Orlowski, A.; Karttunen, M.; Urtti, A.;
Yliperttula, M.; Vuorimaa, E.; Bunker, A. Study of PEGylated lipid layers as a model for PEGylated liposome
surfaces: Molecular dynamics simulation and Langmuir monolayer studies. Langmuir ACS J. Surf. Colloids
2011, 27, 7788–7798. [CrossRef]
59. Cao, Z.; Zhang, L.; Jiang, S. Superhydrophilic zwitterionic polymers stabilize liposomes. Langmuir ACS J.
Surf. Colloids 2012, 28, 11625–11632. [CrossRef]
60. Thamphiwatana, S.; Fu, V.; Zhu, J.; Lu, D.; Gao, W.; Zhang, L. Nanoparticle-stabilized liposomes for
pH-responsive gastric drug delivery. Langmuir ACS J. Surf. Colloids 2013, 29, 12228–12233. [CrossRef]
61. Chen, M.; Xie, S.; Wei, J.; Song, X.; Ding, Z.; Li, X. Antibacterial Micelles with Vancomycin-Mediated
Targeting and pH/Lipase-Triggered Release of Antibiotics. ACS Appl. Mater. Interfaces 2018, 10, 36814–36823.
[CrossRef]
62. Huh, A.J.; Kwon, Y.J. “Nanoantibiotics”: A new paradigm for treating infectious diseases using nanomaterials
in the antibiotics resistant era. J. Control. Release 2011, 156, 128–145. [CrossRef]
63. Hajipour, M.J.; Fromm, K.M.; Ashkarran, A.A.; Jimenez de Aberasturi, D.; de Larramendi, I.R.; Rojo, T.;
Serpooshan, V.; Parak, W.J.; Mahmoudi, M. Antibacterial properties of nanoparticles. Trends Biotechnol. 2012,
30, 499–511. [CrossRef]
Molecules 2019, 24, 1991 15 of 15
64. Muzammil, S.; Hayat, S.; Fakhar-E-Alam, M.; Aslam, B.; Siddique, M.H.; Nisar, M.A.; Saqalein, M.; Atif, M.;
Sarwar, A.; Khurshid, A.; et al. Nanoantibiotics: Future nanotechnologies to combat antibiotic resistance.
Front. Biosci. Elite Ed. 2018, 10, 352–374.
65. Dai, X.; Zhao, Y.; Yu, Y.; Chen, X.; Wei, X.; Zhang, X.; Li, C. Single continuous near-infrared laser-triggered
photodynamic and photothermal ablation of antibiotic-resistant bacteria using effective targeted copper
sulfide nanoclusters. ACS Appl. Mater. Interfaces 2017, 9, 30470–30479. [CrossRef]
66. Edson, J.A.; Kwon, Y.J. Design, challenge, and promise of stimuli-responsive nanoantibiotics. Nano Converg.
2016, 3, 26. [CrossRef]
67. Serpe, L.; Giuntini, F. Sonodynamic antimicrobial chemotherapy: First steps towards a sound approach for
microbe inactivation. J. Photochem. Photobiol. B 2015, 150, 44–49. [CrossRef]
68. Hamblin, M.R.; Brown, S.B. Photodynamic therapy for infectious disease. Adv. Photodyn. Ther. Basic
Transl. Clin. 2008, 359–373.
69. Serpe, L.; Foglietta, F.; Canaparo, R. Nanosonotechnology: The next challenge in cancer sonodynamic therapy.
Nanotechnol. Rev. 2012, 1, 173–182. [CrossRef]
70. Dahl, T.A.; Midden, W.R.; Neckers, D.C. Comparison of photodynamic action by Rose Bengal in gram-positive
and gram-negative bacteria. Photochem. Photobiol. 1988, 48, 607–612. [CrossRef]
71. Sabbahi, S.; Ben Ayed, L.; Jemli, M. Staphylococcus aureus photodynamic inactivation mechanisms by rose
bengal: Use of antioxidants and spectroscopic study. Appl. Water Sci. 2018, 8, 56. [CrossRef]
72. Consoli, G.M.L.; Di Bari, I.; Blanco, A.R.; Nostro, A.; D’Arrigo, M.; Pistarà, V.; Sortino, S. Design, Synthesis,
and Antibacterial Activity of a Multivalent Polycationic Calix [4]arene–NO Photodonor Conjugate. ACSMed.
Chem. Lett. 2017, 8, 881–885. [CrossRef]
73. Black, K.C.L.; Sileika, T.S.; Yi, J.; Zhang, R.; Rivera, J.G.; Messersmith, P.B. Bacterial killing by light-triggered
release of silver from biomimetic metal nanorods. Small 2014, 10, 169–178. [CrossRef]
74. Pallavicini, P.; Bassi, B.; Chirico, G.; Collini, R.M.; Dacarro, G.; Fratini, E.; Grisoli, P.; Patrini, M.; Sironi, L.;
Taglietti, A.; et al. Modular approach for bimodal antibacterial surfaces combining photo-switchable activity
an sustained biocidal release. Sci. Rep. 2017, 7, 5259–5269. [CrossRef]
75. D’Agostino, A.; Taglietti, A.; Grisoli, P.; Dacarro, G.; Cucca, L.; Patrini, M.; Pallavicini, P. Seed mediated
growth of silver nanoplates on glass: Exploiting the bimodal antibacterial effect by near IR photo-thermal
action and Ag+ release. RSC Adv. 2016, 6, 70414–70423. [CrossRef]
76. Cadafalch Gazquez, G.; Smulders, V.; Veldhuis, S.; Wieringa, P.; Moroni, L.; Boukamp, B.; ten Elshof, J.
Influence of Solution Properties and Process Parameters on the Formation and Morphology of YSZ and NiO
Ceramic Nanofibers by Electrospinning. Nanomaterials 2017, 7, 16. [CrossRef]
77. Ballesteros, C.A.S.; Bernardi, J.C.; Correa, D.S.; Zucolotto, V. Controlled Release of Silver Nanoparticles
Contained in Photoresponsive Nanogels. ACS Appl. Bio Mater. 2019, 2, 644–653. [CrossRef]
78. Yadav, H.M.; Otari, S.V.; Bohara, R.A.; Mali, S.S.; Pawar, S.H.; Delekar, S.D. Synthesis and visible
light photocatalytic antibacterial activity of nichel-doped TiO2 nanoparticles against Gram-positive and
Gram-negative bacteria. J. Photochem. Photobiol. A 2014, 294, 130–136. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
